BMS grabs bigger market territory for cancer antibody; Biotech vet Dionne joins Third Rock entrepreneur team;

@FierceBiotech: Report: Just 10% of drug moving through trials between 2003 and 2010 were approved by FDA. Oncology drugs faced toughest road. More | Follow @FierceBiotech

@JohnCFierce: Creating co. on bleeding edge of a new technology can cut both ways. PacBio axes 130 jobs, slams brakes on spending. News | Follow @JohnCFierce

@RyanMFierce: I hope to see lots of Boston biotechies at Oct. 19 breakfast featuring R&D heads at Biogen, Vertex and @JohnCFierce. Info | Follow @RyanMFierce

@MaureenFierce: RT @thecortex: Merck boss uses 12 different names for "job-cut" in memo. Report | Follow @MaureenFierce

> Bristol-Myers Squibb has expanded its commercial footprint on an experimental cancer treatment partnered with Japan's Ono. Its expanded its territorial rights to develop and commercialize the anti-PD-1 antibody known as BMS-936558/ONO-4538 to the global market, excepting only Japan, Korea and Taiwan. BMS snagged the drug in its acquisition of Medarex. Release

> Keith Dionne, the former CEO at Surface Logix, has joined Third Rock as an entrepreneur-in-residence. Dionne is a longtime biotech player and a veteran of Millennium, so he'll be a familiar face to many at Third Rock. Release

> Zafgen, the virtual Cambridge, MA-based biotech out to come up with a therapeutic alternative to bariatric surgery in treating obesity, named Dr. Dennis Kim as its chief medical officer. Zafgen release

> Viiv Healthcare has withdrawn European and U.S. applications for "once-daily administration of Celsentri/Selzentry [maraviroc] tablets in treatment-experienced patients infected with only CCR5-tropic HIV-1." Story

> Sanofi Pasteur is donating a vaccine strain used for polio eradication to the World Health Organization. Release

Pharma News

@FiercePharma: Scientists who worked on targeted leukemia meds--Novartis' Gleevec, BMS' Sprycel--make Nobel predictions list Story | Follow @FiercePharma

> Pfizer blames Spanish job cuts on pricing policies. Article

> U.K. pharma pushes back against value-based pricing. Item

Medical Device News

@FierceMedDev: Medtronic awarded $101.2M in patent infringement case. Article | Follow @FierceMedDev

> Boston Sci prevails in lawsuit over sales group. Story

> Former Wright exec takes reins at Intrinsic. Report

Drug Delivery News

> Feds back nasal med for cyanide poisoning. Report

> Lasers craft neuron-delivery 'trucks' for Alzheimer's. Piece

> Ultrasound could aid delivery of drugs into brain. Item

> Alkermes wraps buyout of Elan drug-delivery biz. Story

> Unigene, Tarsa score Ph3 win with oral peptide drug. Item

> Sanofi fuels microneedle trend with flu vax. More

And Finally... Researchers say that yawning varies with the season, suggesting it may be a simple method the body relies on to regulate brain temperature. Release

Suggested Articles

The inclusion of Kupffer cells in in vitro hepatic cultures provides researchers with advanced tools for disease modeling and drug discovery.

A delay to Moderna's phase 3 COVID-19 study is part of a trend of tensions in the biotech’s relationship with the U.S. government, Reuters reported.

GlaxoSmithKline is continuing its strategy of giving out access to its vaccine platform as it adds Medicago to its growing partners list.